Know Cancer

or
forgot password

Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer


Phase 4
18 Years
N/A
Not Enrolling
Both
Esophageal Cancer

Thank you

Trial Information

Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer


Further informations will be provided by Centre Oscar Lambret.


Inclusion Criteria:



- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a),
histologically proven

- Treated by exclusive concomitant radiochemotherapy

- Written informed consent

Exclusion Criteria:

- Presence of a second uncontrolled cancer

- Metastatic carcinoma

- Metastatic disease, except cervical lymphnodes... (M1a)

- In situ carcinoma

- Eso-gastric junction cancer (Siewert II ou III)

- Inclusion in a clinical trial with an experimental drug during the study and until 15
weeks after the end of radiotherapy)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry

Outcome Time Frame:

15 weeks after the end of irradiation

Safety Issue:

No

Principal Investigator

ADENIS Antoine, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Oscar Lambret

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

2006-13

NCT ID:

NCT00911092

Start Date:

October 2007

Completion Date:

December 2011

Related Keywords:

  • Esophageal Cancer
  • Oesophageal cancer
  • exclusive concomitant radiochemotherapy
  • Esophageal Diseases
  • Esophageal Neoplasms

Name

Location